skip to content

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

Media

Media releases
view all

stay updated

get the latest news and updates to your inbox.